Harima-Kyowa Co Ltd

Harima-Kyowa maintains a conservative capital structure with a debt-to-equity ratio of 0.1, indicating minimal leverage and a strong equity base. The company's liquidity position is reflected in a current ratio of 2.04, suggesting it has sufficient short-term assets to cover its liabilities. However, the company reported negative free cash flow of -1.95 billion JPY, driven by capital expenditures of -3.54 billion JPY, which may signal reinvestment in operations or asset expansion. In terms of profitability, Harima-Kyowa's return on equity (ROE) of 5.2% and return on assets (ROA) of 3.55% are below the typical thresholds for high-performing firms in the Pharmaceuticals & Medical Research sector. These metrics suggest the company is generating modest returns relative to its equity and asset base. The company operates a single Wholesale segment, with no disclosed geographic diversification in the provided data. This lack of segment and geographic detail limits the ability to assess exposure to regional market risks or growth opportunities. Harima-Kyowa's revenue for the latest period was 61.82 billion JPY, with no disclosed growth rate or forecast. Analysts estimated revenue at 62.04 billion JPY, indicating a slight positive variance. The company's capital expenditures and negative free cash flow suggest a focus on operational expansion or asset renewal, though the long-term implications of this strategy remain unclear. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The low dilution risk is supported by a lack of recent equity issuance or dilutive events, and the company's shares outstanding remain stable between basic and diluted shares. Recent financial filings and transcripts do not provide additional insights into strategic shifts or operational changes. The company's business model appears stable, with no major disruptions or events reported in the latest available data.